155 related articles for article (PubMed ID: 34793664)
1. Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens.
Kourea HP; Dimitrakopoulos FI; Koliou GA; Batistatou A; Papadopoulou K; Bobos M; Asimaki-Vlachopoulou A; Chrisafi S; Pavlakis K; Chatzopoulos K; Galani E; Pentheroudakis G; Pectasides D; Bafaloukos D; Res E; Papakostas P; Koutras A; Kotoula V; Fountzilas G
Cancer Res Treat; 2022 Oct; 54(4):1053-1064. PubMed ID: 34793664
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
3. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.
Goussia A; Simou N; Zagouri F; Manousou K; Lazaridis G; Gogas H; Koutras A; Sotiropoulou M; Pentheroudakis G; Bafaloukos D; Markopoulos C; Patsea H; Christodoulou C; Papakostas P; Zaramboukas T; Samantas E; Kosmidis P; Venizelos V; Karanikiotis C; Papatsibas G; Xepapadakis G; Kalogeras KT; Bamia C; Dimopoulos MA; Malamou-Mitsi V; Fountzilas G; Batistatou A
PLoS One; 2018; 13(7):e0200302. PubMed ID: 30063723
[TBL] [Abstract][Full Text] [Related]
4. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis.
Zheng CL; Qiu C; Shen MX; Qu X; Zhang TH; Zhang JH; Du JJ
Asian Pac J Cancer Prev; 2015; 16(5):1881-95. PubMed ID: 25773840
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
7. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
8. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC
Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832
[TBL] [Abstract][Full Text] [Related]
9. Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx.
Pentheroudakis G; Nicolaou I; Kotoula V; Fountzilas E; Markou K; Eleftheraki AG; Fragkoulidi A; Karasmanis I; Tsigka A; Angouridakis N; Vlachtsis K; Nikolaou A; Pavlidis N; Fountzilas G
Oral Oncol; 2012 Aug; 48(8):709-16. PubMed ID: 22366437
[TBL] [Abstract][Full Text] [Related]
10. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.
Zhang Q; Lu S; Li T; Yu L; Zhang Y; Zeng H; Qian X; Bi J; Lin Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):173. PubMed ID: 31023337
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
Nasir A; Reising LO; Nedderman DM; Fulford AD; Uhlik MT; Benjamin LE; Schade AE; Holzer TR
Anticancer Res; 2016 Jun; 36(6):2683-96. PubMed ID: 27272777
[TBL] [Abstract][Full Text] [Related]
12. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.
Lattanzio R; La Sorda R; Facciolo F; Sioletic S; Lauriola L; Martucci R; Gallo E; Palmieri G; Evoli A; Alessandrini G; Ruco L; Rendina EA; Truini M; Chiarle R; Barreca A; Pich A; Ascani S; Remotti D; Tunesi G; Granone P; Ratto GB; Puma F; Pescarmona E; Piantelli M; Marino M; ; Carlini S; Cerasoli V; Corzani F; Melis E; Filippetti M; Canalini P; Palestro G; Lalle M; Ruffini E; Ceribelli A; Rinaldi M
Lung Cancer; 2014 Aug; 85(2):191-6. PubMed ID: 24908332
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma.
Wang J; Taylor A; Showeil R; Trivedi P; Horimoto Y; Bagwan I; Ewington L; Lam EW; El-Bahrawy MA
Cytokine; 2014 Aug; 68(2):94-100. PubMed ID: 24845798
[TBL] [Abstract][Full Text] [Related]
14. Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
Holzer TR; Fulford AD; Reising LO; Nedderman DM; Zhang X; Benjamin LE; Schade AE; Nasir A
Anticancer Res; 2016 Jul; 36(7):3277-88. PubMed ID: 27354584
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.
Lee TH; Seng S; Sekine M; Hinton C; Fu Y; Avraham HK; Avraham S
PLoS Med; 2007 Jun; 4(6):e186. PubMed ID: 17550303
[TBL] [Abstract][Full Text] [Related]
17. ZLM-7 inhibits the occurrence and angiogenesis of breast cancer through miR-212-3p/Sp1/VEGFA signal axis.
Li X; Zou ZZ; Wen M; Xie YZ; Peng KJ; Luo T; Liu SY; Gu Q; Li JJ; Luo ZY
Mol Med; 2020 Nov; 26(1):109. PubMed ID: 33187481
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
19. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.
Zhang Z; Neiva KG; Lingen MW; Ellis LM; Nör JE
Cell Death Differ; 2010 Mar; 17(3):499-512. PubMed ID: 19834490
[TBL] [Abstract][Full Text] [Related]
20. Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2.
Sadremomtaz A; Kobarfard F; Mansouri K; Mirzanejad L; Asghari SM
J Recept Signal Transduct Res; 2018; 38(5-6):432-441. PubMed ID: 30929546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
